Novo Nordisk (NVO.US) Q2 earnings surpass expectations and full-year guidance is raised, but concerns remain as Wegovy oral drug sales are sluggish and the path back to growth is still overshadowed.

智通财经2026/08/05 08:01

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zhito Finance APP reports that although Novo Nordisk (NVO.US) announced better-than-expected results for the second quarter of 2026 and raised its full-year guidance, it did not address Wall Street's main concern—whether, as competition in the weight-loss drug market intensifies, this Danish pharmaceutical giant can find a clear path back to sustainable growth.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novo Nordisk (NVO.US) Q2 earnings surpass expectations and full-year guidance is raised, but concerns remain as Wegovy oral drug sales are sluggish and the path back to growth is still overshadowed.

You may also like

Crypto prices